We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $159K invested in Array Biopharma Inc in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 316 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 318 → 1 (-317)

100% less funds holding in top 10

Funds holding in top 10: 28 → 0 (-28)

100% less capital invested

Capital invested by funds: $10.5B → $159K (-$10.5B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 316

Holders
1
Holders Change
-317
Holders Change %
-99.69%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-28
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
316
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$943M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$890M
3
BlackRock
BlackRock
New York
-$824M
4
RG
Redmile Group
California
-$405M
5
FCM
Farallon Capital Management
California
-$394M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
126
Prudential Financial
New Jersey
– -$8.06M -173,911 Closed
BC
127
Birchview Capital
Vermont
– -$7.78M -168,000 Closed
Rafferty Asset Management
128
Rafferty Asset Management
New York
– -$7.74M -167,089 Closed
TI
129
TT International
United Kingdom
– -$7.64M -165,000 Closed
Thrivent Financial for Lutherans
130
Thrivent Financial for Lutherans
Minnesota
– -$7.61M -164,153 Closed
Calamos Advisors
131
Calamos Advisors
Illinois
– -$7.58M -163,651 Closed
Marshall Wace
132
Marshall Wace
United Kingdom
– -$7.54M -162,861 Closed
CM
133
Castleark Management
Illinois
– -$7.52M -162,251 Closed
PWPCM
134
Perella Weinberg Partners Capital Management
New York
– -$7.41M -159,849 Closed
N
135
Natixis
France
– -$7.11M -153,536 Closed
CEP
136
Chicago Equity Partners
Illinois
– -$7.08M -152,795 Closed
Manulife (Manufacturers Life Insurance)
137
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$6.85M -147,888 Closed
SCC
138
Spring Creek Capital
Kansas
– -$6.72M -145,000 Closed
MSL
139
Mackay Shields LLC
New York
– -$6.57M -141,821 Closed
AIG
140
American International Group
New York
– -$6.57M -141,711 Closed
PAM
141
Panagora Asset Management
Massachusetts
– -$6.31M -136,133 Closed
VOAM
142
Vertex One Asset Management
British Columbia, Canada
– -$6.25M -135,000 Closed
CSS
143
Cubist Systematic Strategies
Connecticut
– -$6.24M -134,582 Closed
SAM
144
Silphium Asset Management
United Kingdom
– -$6.07M -131,000 Closed
BPGAM
145
BTG Pactual Global Asset Management
Bermuda
– -$5.93M -128,000 Closed
EAM
146
Erste Asset Management
Austria
– -$5.91M -127,800 Closed
PNC Financial Services Group
147
PNC Financial Services Group
Pennsylvania
– -$5.83M -125,790 Closed
Axa
148
Axa
France
– -$5.79M -124,920 Closed
Legal & General Group
149
Legal & General Group
United Kingdom
– -$5.56M -119,925 Closed
BFM
150
Boothbay Fund Management
New York
– -$5.54M -119,526 Closed
4 5
6
7 8

ARRY Hedge Fund Activity: Q3 2019 in Review

1 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2019, worth a combined $159K — down 100% from $10.5B a quarter earlier.

Sellers outnumbered buyers: 316 funds closed out of ARRY and 0 opened new positions — a net loss of 316 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $943M sold.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q3 2019, down from 318 in Q2 2019.
  • Funds reported $159K of Array Biopharma Inc stock for Q3 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Array Biopharma Inc positions in Q3 2019 and 316 closed out, a net change of -316 holders.
  • The largest Array Biopharma Inc seller in Q3 2019 was Vanguard Group, an estimated $943M sold.

Based on aggregated 13F filings for Q3 2019.